Trials
Search / Trial NCT06440603

EKLF Gene Expression in β-thalassemia

Launched by ROFAIDA HASSAN AHMED · May 31, 2024

Apply for Trial

Trial Information

Current as of March 13, 2025

Not yet recruiting

Keywords

ClinConnect Summary

β-thalassemia is a common inherited disorder caused by absent or reduced synthesis of the hemoglobin subunit beta (beta globin chain) , it has 3 clinical types; minor which is a carrier state, intermedia and major which are differentiated by blood transfusion dependency and lab findings.

In β-thalassemia, insufficient production of the β-globin molecule results in an excess of free α-globin chains that can precipitate within erythroid precursors, impairing their maturation and leads to death of these precursors and ineffective production of erythroid cells. As a result, a significant anaem...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • patients with β-thalassemia (major and intermedia).
  • • patients are of both sexes (male or female) at any age
  • Exclusion Criteria:
  • • patients with any other types of hemolytic anaemia

Trial Officials

Eman Naser Eldin

Study Director

Assiut University

Sherif Helmy

Study Director

Assiut University

Reem Elagoz

Study Director

Assiut University

About Rofaida Hassan Ahmed

Rofaida Hassan Ahmed is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a strong focus on innovative therapeutic solutions, Ms. Ahmed leads initiatives that prioritize rigorous scientific methodologies and ethical standards. Her expertise encompasses a wide range of therapeutic areas, ensuring that clinical trials are designed and executed with precision and integrity. Through collaboration with healthcare professionals and research institutions, she aims to facilitate the development of cutting-edge treatments that address pressing health concerns.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0